|
|
|
|
|
Highlights from the 2022 American Urological Association Annual Meeting |
|
|
|
|
| Bladder Cancer: Epidemiology & Evaluation I
|
|
| Is A Restaging TURBT Necessary in High Risk NMIBC if the Initial TURBT Was Performed Using Blue Light?
|
| Muhannad Alsyouf, MD
|
| Muhannad Alsyouf discussed whether a restaging TURBT is necessary for high risk Non-Muscle Invasive Bladder Cancer (NMIBC) if the initial TURBT was performed using blue light. TURBT using blue light cystoscopy/HAL does not reduce rates of residual disease or risk of upstaging on restaging TURBT in high risk NMIBC. Thus, a restaging TURBT is still necessary even if initial TURBT was performed using blue light cystoscopy/HAL.
|
|
|
|
|
|
| Long-term Follow-up of Intravesical Gemcitabine and Docetaxel as Rescue Therapy for NMIBC
|
| Michael A. O’Donnell, MD
|
| Michael O’Donnell discussed long-term follow-up of intravesical gemcitabine and docetaxel as rescue therapy for non-muscle invasive bladder cancer (NMIBC). While radical cystectomy remains the preferred treatment for bacillus Calmette-Guérin (BCG) unresponsive high-risk NMIBC, many patients are either unwilling or unfit to undergo surgery.
|
|
|
|
|
|
| Bladder Cancer: Non-Invasive I |
| A Randomized Study to Compare Outcomes of Intravesical Chemohyperthermia with Mitomycin C Versus Intravesical BCG for Intermediate and High Risk NMIBC
|
| Karandeep Guleria, MD, MS
|
| Karandeep Guleria discussed a randomized study assessing intravesical chemohyperthermia with Mitomycin C versus intravesical BCG for intermediate and high risk non-muscle invasive bladder cancer (NMIBC). Based on these results, chemohyperthermia is an alternative option to intravesical BCG therapy as adjuvant treatment for intermediate and high-risk NMIBC.
|
|
|
|
|
|
| En-Bloc Versus Conventional Transurethral Resection of Bladder Tumors: Single-Center Prospective Randomized Trial
|
| Alberto Breda, MD
|
| Alberto Breda discussed the results of a single-center randomized trial assessing en-bloc versus conventional transurethral resection of bladder tumors (TURBT). TURBT is considered the gold standard in the diagnosis and risk stratification of bladder cancer. En-bloc resection of bladder tumor is non-inferior to TURBT in pathological, surgical, and short term oncological outcomes.
|
|
|
|
|
|
| Real-Time Bladder Tumor Detection at Clinics in Flexible Cystoscopy with White Light and Narrow Band Imaging using Deep Learning
|
| Atsushi Ikeda, MD, Ph.D.
|
| Atsushi Ikeda discussed real-time bladder tumor detection at clinics in flexible cystoscopy with white light and narrow band imaging using deep learning. Non-muscle invasive bladder cancer (NMIBC) is the most common clinical condition observed during the diagnosis of bladder cancer and is often a chronic condition that requires frequent cystoscopy.
|
|
|
|
|
|
|
|
| Management of Incidentally Discovered 3cm Solid Renal Mass Cancer: Panel Discussion |
| Costas Lallas MD; Brian Lane MD; Lee Ponsky MD; and Jaime Landman MD |
| Friday morning at the 2022 AUA kicked off with a panel discussion consisting of thought leaders in the management of incidentally found 3cm solid renal masses. Costas Lallas moderated the session which began with four-minute presentations from each panelist, Brian Lane, Lee Ponsky, and Jaime Landman. |
|
|
|
|
|
| Society of Urologic Oncology (SUO) |
| Should Everyone Receive Adjuvant Therapy after Resection of High-Risk RCC?
|
| Viraj Master, MD, PhD, FACS
|
| Viraj Master discussed whether everyone should receive adjuvant therapy after resection of high-risk renal cell carcinoma (RCC). Dr. Master started his presentation by noting that the perfect adjuvant therapy would be inexpensive, easy to tolerate, active in microscopic disease, and would provide good outcomes.
|
|
|
|
|
|
| Kidney Cancer: Localized: Surgical Therapy I |
| The Impact Of Primary Tumor Size On Cancer-Specific And All-Cause Mortality In Patients Undergoing Cytoreductive Nephrectomy For mRCC: Analysis From The International Marker Consortium For Renal Cancer |
| Ryan Isaac Nasseri, MD, BS |
| In a moderated poster presentation at the 2022 American Urologic Association Annual Meeting held in New Orleans and virtually, Dr. Nasseri presented results of an analysis examining the effect of primary tumor size on survival for patients undergoing cytoreductive nephrectomy (CN). |
|
|
|
|
|
|
|
|
|
|
| Comparison of One-Year Healthcare Expenditure and Utilizations between Robotic-assisted versus Laparoscopic Surgery among Patients Undergoing Partial and Radical Nephrectomy |
| Kennedy Okhawere, MD, MPH |
| Kennedy Okhaware presented results of a comparison of health care cost and utilization according to surgical approach (robotic versus laparoscopic) among patients undergoing partial and radial nephrectomy. For partial and radical nephrectomy, robotic-assisted surgery has comparable health care utilization and total one-year post discharge cost to a laparoscopic approach. Further research is warranted to evaluate the impact of the surgical approach on post-operative kidney function and consequent economic burdens. |
|
|
|
|
|
|
|
| Urology Resident Autonomy Compared to General Surgery Resident Autonomy
|
| Anh Nguyen, MD
|
| Anh Nguyen, on behalf of Kunj Jain and the team from Rutgers New Jersey Medical School, shed light on a concerning dilemma on the educational side of health care. In recent years, there has been a rise in urology and general surgery residents who voice a lack of surgical preparedness. Residents have expressed that this lack of preparedness stems from having less autonomy in the operating room. It has been hypothesized that the decrease of resident autonomy could be attributed to the concern of operating times, possible surgery related complications, and poor operation results.
|
|
|
|
|
|
 |
